Endothelin receptor antagonists in cardiology clinical trials

Expert Opinion on Investigational Drugs

Volumn 11, Issue 3, 2002, Pages 431-443

  Neunteufl, Thomas ^a   Berger, Rudolf ^a   Pacher, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arterial hypertension; Clinical trials; Congestive heart failure; Coronary artery disease; Endothelin receptor antagonist; Pulmonary hypertension

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ATRASENTAN; BMS 193884; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; NITRIC OXIDE; PLACEBO; SITAXSENTAN; TAK 044; TEZOSENTAN; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CARDIOLOGY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG SELECTIVITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PULMONARY HYPERTENSION; RAT; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ANTAGONISM; METABOLISM; REVIEW; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 0036200833     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.3.431     Document Type: Article

References (101)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin 1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme
3. Purification and characterization of endothelin-converting enzyme from rat lung
4. Purification and characterization of endothelin-converting enzyme from rat lung
5. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells
6. Endothelin ET(A) and ET(B) receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
7. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease
8. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
9. Release of endothelin from the porcine aorta: Inhibition by endothelium-derived nitric oxide
10. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction
11. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells
12. Mechanisms involved in the stimulation of aldosterone production by angiotensin II, vasopressin and endothelin
13. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET (A)-receptor antagonist
14. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines
15. Endothelin-1 has a priming effect on production of superoxide anion by alveolar macrophages: Its possible correlation with bronchopulmonary dysplasia
16. Endothelin receptor B subtype B mediates autoinduction of endothelin-1 in rat mesangial cells
17. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
18. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
19. Plasma endothelin in chronic heart failure
20. Endothelin in human congestive heart failure
21. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
22. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
23. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
24. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
25. Plasma endothelin concentrations in humans with end stage heart failure and after heart transplantation
26. Role of endothelin in the exercise intolerance of chronic heart failure
27. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
28. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-1 trial
29. Actelion shows accelerated growth for second quarter
30. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure
31. RITZ (Randomized Intravenous TeZosentan) II
32. RITZ (Randomized Intravenous TeZosentan) I
33. RITZ (Randomized Intravenous TeZosentan) IV
34. Phase III trial of intravenous endothelin receptor antagonist tezosentan for acute heart failure shows positive hemodynamic results
35. Banyu's new drugs R&D pipeline
36. Acute hemodynamic and neurohumoral effects of selective ETA-receptor blockade in patients with congestive heart failure
37. Chronic selective ETA receptor blockade in congestive heart failure: The HEAT trial (Heart failure ETA receptor blockade trial)
38. Neurohumoral and hemodynamic effects of the selective endothelin antagonist LU 135252 in advanced heart failure
39. Selective ETA blockade improves hemodynamics without neurohumoral activation or impairment of renal function in congestive heart failure
40. Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure
41. Improved hemodynamics with the ETA selective receptor antagonist BMS-193884 in patients with heart failure
42. Discovery of BMS-193884, a potent and selective ETA receptor antagonist
43. Endothelin mediates local pulmonary vascular tone in patients with heart failure: Demonstration by direct intrapulmonary infusion of sitaxsentan
44. Texas Biotechnology reports positive Phase IIa trial results of endothelin receptor antagonist in CHF
45. Texas Biotechnology reports additional positive Phase IIA trial results in congestive heart failure
46. Product development pipeline: February 2001
47. Contractile and arrhythmic effects of endothelin receptor antagonists in human heart in vitro: Blockade with SB 209670
48. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion
49. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries
50. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
51. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
52. Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration
53. Endothelin in cardiovascular disease: From atherosclerosis to heart failure
54. Circulating endothelin in acute ischemic syndromes
55. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction
56. Plasma endothelin determination as a prognostic indicator of one year mortality after acute myocardial infarction
57. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
58. Role of Endothelin-1 in the active constriction of human atherosclerotic coronary arteries
59. Knoll and Hoechst Marion Roussel announce alliance to codevelop compound for chronic heart failure and high blood pressure
60. Drug development pipeline-Abbott Laboratories. From a presentation by Miles D White CEO of Abbott at the Merrill Lynch Global Healthcare Conference. February 6-8, 2001
61. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor
62. Pharmacology of a non-selective ET(A) and ET(B) receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats
63. Effects of TAK-044, an endothelin receptor antagonist, in a canine model of ischemia-reperfusion induced myocardial infarction
64. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
65. Enhanced coronary vasoconstriction to endothelin-B receptor activation in experimental congestive heart failure
66. Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: A comparison of selective ET(A) receptor antagonism and dual ET(A/B) receptor antagonism using BQ-1223 and SB 209670
67. Selective ET(A) receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat
68. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model
69. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol
70. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats
71. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats
72. Structure and function of small arteries in salt-induced hypertension-effects of chronic endothelin-subtype-A-receptor blockade
73. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats
74. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1
75. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: A possible endogenous endothelin-1 mediated mechanism
76. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo acute effects of bosentan, an orally active, mixed endothelin ET-A and ET-B receptor antagonist
77. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
78. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
79. Texas Biotechnology reports progress on Endothelin A receptor antagonist program
80. Endothelins; new therapeutic opportunities
81. Wallstreet analysts meeting
82. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
83. ET(A) receptor blockade prevents increased tissue endothelin-1 vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension
84. Endothelin-1 potentiates smooth muscle cell growth to PDGF: Role of ETA and ETB receptor blockade
85. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research group
86. Primary pulmonary hypertension
87. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
88. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
89. Relation of endothelin-1 to survival in patients with primary hypertension
90. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study
91. Oral endothelin receptor antagonist Tracleer meets primary endpoint in pulmonary arterial hypertension study
92. Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension
93. ICOS Corporation and Texas Biotechnology Corporation initiate a pivotal trial in pulmonary arterial hypertension
94. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
95. Primary pulmonary hypertension: Natural history and the importance of thrombosis
96. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
97. Endothelin antagonism with bosentan: A review of potential applications